HSCS (HeartSciences) YoY EBITDA Growth: 54.92% (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HSCS HeartSciences Inc HSCS
22 GF Score
Price $2.78
GF Value $0.54
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is HeartSciences YoY EBITDA Growth?

HeartSciences HSCS +12.45% 22 YoY EBITDA Growth is 54.92% as of Apr. 2026. GuruFocus rates HSCS with a GF Score™ of 22/100 and a GF Value™ of $0.54 (Significantly Overvalued). The stock has 9 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. HeartSciences's YoY EBITDA Growth for the quarter that ended in Apr. 2026 was 54.92%.

HeartSciences's EBITDA per Share for the three months ended in Apr. 2026 was $-0.79.

HeartSciences YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for HeartSciences's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeartSciences YoY EBITDA Growth Chart

HeartSciences Annual Data
Trend Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
YoY EBITDA Growth
Get a 7-Day Free Trial -91.39 -36.59 76.65 50.26 63.73

HeartSciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.72 45.01 65.19 74.67 54.92
HSCS
22GF Score
HeartSciences Inc HSCS
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HeartSciences YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

HeartSciences's YoY EBITDA Growth for the fiscal year that ended in Apr. 2026 is calculated as:

YoY EBITDA Growth (A: Apr. 2026 )
=(EBITDA per Share (A: Apr. 2026 )-EBITDA per Share (A: Apr. 2025 ))/ | EBITDA per Share (A: Apr. 2025 ) |
=(-3.146--8.675)/ | -8.675 |
=63.73 %

HeartSciences's YoY EBITDA Growth for the quarter that ended in Apr. 2026 is calculated as:

YoY EBITDA Growth (Q: Apr. 2026 )
=(EBITDA per Share (Q: Apr. 2026 )-EBITDA per Share (Q: Apr. 2025 )) / | EBITDA per Share (Q: Apr. 2025 )) |
=(-0.792--1.757)/ | -1.757 |
=54.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 54.92% mean?
HeartSciences (HSCS) has a YoY EBITDA Growth of 54.92% as of Apr. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for HeartSciences and its competitors.
Is HeartSciences' YoY EBITDA Growth too high?
HeartSciences' current YoY EBITDA Growth is 54.92%. Overall, HeartSciences has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HeartSciences' YoY EBITDA Growth compare to CODX and NVNO?
HeartSciences' YoY EBITDA Growth of 54.92% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for HeartSciences and its competitors. HeartSciences's current YoY EBITDA Growth is 54.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeartSciences stock overvalued right now?
Based on GuruFocus' analysis, HeartSciences (HSCS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.54, compared to a current price of $2.78 — trading 414.8% above its estimated fair value. The current YoY EBITDA Growth is 54.92%. HeartSciences' overall GF Score™ is 22/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For HeartSciences (HSCS), the current YoY EBITDA Growth is 54.92% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HeartSciences (HSCS) Overvalued in 2026?

Based on GuruFocus' analysis, HeartSciences stock appears to be overvalued. The current stock price of $2.78 is trading 414.8% above its estimated GF Value™ of $0.54. GuruFocus considers HeartSciences to be Significantly Overvalued.

Key valuation signals for HSCS:

  • YoY EBITDA Growth: 54.92%
  • GF Value™: $0.54 vs. price of $2.78 (414.8% above fair value)
  • GF Score™: 22/100 with 9 warning signs

No single metric tells the full story. See the HSCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HeartSciences Business Description

Address 550 Reserve Street, Suite 360, Southlake, TX, USA, 76092
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
22GF Score

Get the complete analysis for HSCS

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.78
Price
$0.54
GF Value